130 related articles for article (PubMed ID: 12501127)
1. Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers.
Eiznhamer DA; Creagh T; Ruckle JL; Tolbert DT; Giltner J; Dutta B; Flavin MT; Jenta T; Xu ZQ
HIV Clin Trials; 2002; 3(6):435-50. PubMed ID: 12501127
[TBL] [Abstract][Full Text] [Related]
2. Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects.
Creagh T; Ruckle JL; Tolbert DT; Giltner J; Eiznhamer DA; Dutta B; Flavin MT; Xu ZQ
Antimicrob Agents Chemother; 2001 May; 45(5):1379-86. PubMed ID: 11302799
[TBL] [Abstract][Full Text] [Related]
3. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.
Buckheit RW; White EL; Fliakas-Boltz V; Russell J; Stup TL; Kinjerski TL; Osterling MC; Weigand A; Bader JP
Antimicrob Agents Chemother; 1999 Aug; 43(8):1827-34. PubMed ID: 10428899
[TBL] [Abstract][Full Text] [Related]
4. Quantification of (+)-calanolide A, a novel and naturally occurring anti-HIV agent, by high-performance liquid chromatography in plasma from rat, dog and human.
Xu ZQ; Norris KJ; Weinberg DS; Kardatzke J; Wertz P; Frank P; Flavin MT
J Chromatogr B Biomed Sci Appl; 2000 Jun; 742(2):267-75. PubMed ID: 10901131
[TBL] [Abstract][Full Text] [Related]
5. Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects.
Zhou XJ; Pietropaolo K; Damphousse D; Belanger B; Chen J; Sullivan-Bólyai J; Mayers D
Antimicrob Agents Chemother; 2009 May; 53(5):1739-46. PubMed ID: 19223643
[TBL] [Abstract][Full Text] [Related]
6. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
Boyle A; Moss CE; Marzolini C; Khoo S
Clin Pharmacokinet; 2019 Dec; 58(12):1553-1565. PubMed ID: 31388941
[TBL] [Abstract][Full Text] [Related]
8. Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial.
Schürmann D; Rudd DJ; Zhang S; De Lepeleire I; Robberechts M; Friedman E; Keicher C; Hüser A; Hofmann J; Grobler JA; Stoch SA; Iwamoto M; Matthews RP
Lancet HIV; 2020 Mar; 7(3):e164-e172. PubMed ID: 31911147
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.
Huang F; Koenen-Bergmann M; Macgregor TR; Ring A; Hattox S; Robinson P
Antimicrob Agents Chemother; 2008 Dec; 52(12):4300-7. PubMed ID: 18824608
[TBL] [Abstract][Full Text] [Related]
10. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Martin DE; Blum R; Doto J; Galbraith H; Ballow C
Clin Pharmacokinet; 2007; 46(7):589-98. PubMed ID: 17596104
[TBL] [Abstract][Full Text] [Related]
11. Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1.
Currens MJ; Gulakowski RJ; Mariner JM; Moran RA; Buckheit RW; Gustafson KR; McMahon JB; Boyd MR
J Pharmacol Exp Ther; 1996 Nov; 279(2):645-51. PubMed ID: 8930167
[TBL] [Abstract][Full Text] [Related]
12. Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.
Morse GD; Reichman RC; Fischl MA; Para M; Leedom J; Powderly W; Demeter LM; Resnick L; Bassiakos Y; Timpone J; Cox S; Batts D
Antiviral Res; 2000 Jan; 45(1):47-58. PubMed ID: 10774589
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical properties of related calanolide compounds with activity against human immunodeficiency virus.
Newman RA; Chen W; Madden TL
J Pharm Sci; 1998 Sep; 87(9):1077-80. PubMed ID: 9724557
[TBL] [Abstract][Full Text] [Related]
14. Calanolides, the naturally occurring anti-HIV agents.
Xu ZQ; Flavin MT; Jenta TR
Curr Opin Drug Discov Devel; 2000 Mar; 3(2):155-66. PubMed ID: 19649847
[TBL] [Abstract][Full Text] [Related]
15. Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients.
Thompson MA; Kessler HA; Eron JJ; Jacobson JM; Adda N; Shen G; Zong J; Harris J; Moxham C; Rousseau FS;
AIDS; 2005 Oct; 19(15):1607-15. PubMed ID: 16184030
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase.
Quan Y; Motakis D; Buckheit R; Xu ZQ; Flavin MT; Parniak MA; Wainberg MA
Antivir Ther; 1999; 4(4):203-9. PubMed ID: 10723499
[TBL] [Abstract][Full Text] [Related]
18. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers.
Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
J Clin Pharmacol; 2001 Oct; 41(10):1098-105. PubMed ID: 11583478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
